Summary
Pasireotide LAR had a dose-proportional relationship with dose exposure over a 40- to 60-mg range. Efficacy end points of levels of growth hormone and IGF-1 were correlated with pasireotide exposure, and response rates were higher at the higher pasireotide dose.
- PAOLA
- NCT01137682
- pasireotide
- acromegaly
- growth hormone
- and insulin-like growth factor
- IGF-1
- somatostatin analogs
- endocrinology, diabetes & metabolism clinical trials
- pituitary gland disorders
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.